Sentences with phrase «hematopoietic stem cell transplantation for»

«We are actively involved in expanding the possible resources for hematopoietic stem cell transplantation for these patients.»

Cuvelier GD, Schultz KR, Davis J, Hirschfeld AF, Junker AK, Tan R, Turvey SE.: Optimizing outcomes of hematopoietic stem cell transplantation for severe combined immunodeficiency.

Studies to improve the knowledge of genetic diseases include the natural history study for MLD, advanced diagnosis and natural history of primary immunodeficiencies and immunedysregulatory disorder, and immune reconstitution after hematopoietic stem cell transplantation for genetic disorders.

Mehta J, Gordon LI, Tallman MS, et al., Does younger donor age affect the outcome of reduced - intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

Not exact matches

UTSW co-authors include: Co-lead author Maria Winter, a research associate; Dr. Luisella Spiga, a postdoctoral researcher; visiting fellow Lisa Büttner; graduate students Elizabeth Hughes and Caroline Gillis, all of Microbiology; Dr. Breck Duerkop, Instructor, Immunology; Cassie Behrendt, a research technician, Immunology; Dr. Lora Hooper, Professor and Chair of Immunology with appointments in Microbiology and in the Center for the Genetics of Host Defense, a HHMI Investigator and holder of the Jonathan W. Uhr, M.D. Distinguished Chair in Immunology, and the Nancy Cain and Jeffrey A. Marcus Scholar in Medical Research, in Honor of Dr. Bill S. Vowell; Dr. Luis Sifuentes - Dominguez, Instructor of Pediatrics; Dr. Kayci Huff - Hardy, clinical fellow, Internal Medicine in the Division of Digestive and Liver Diseases; Dr. Andrew Koh, Associate Professor of Pediatrics and Microbiology and in the Harold C. Simmons Comprehensive Cancer Center as well as Director of Pediatric Hematopoietic Stem Cell Transplantation at Children's Health; and Dr. Ezra Burstein, Professor of Internal Medicine and Molecular Biology and Chief of the Division of Digestive and Liver Diseases.

«Proper blood cell production is dependent on functioning hematopoietic stem and progenitor cells that are destroyed during conditioning procedures for transplantation or following bone marrow injury,» said the study's first author Kevin A. Goncalves, who performed this research as part of his PhD studies in cellular and molecular physiology at the Sackler School.

Autologous hematopoietic stem cell transplantation (AHSCT) has been investigated as a treatment for aggressive MS, the rationale for which is immune reconstitution.

Hematopoietic stem cell transplantation (HSCT), once considered an effective yet risky alternative to drug therapy for blood cancer, has become more accessible and successful in a wide range of patients as a result of major advances in transplant strategies and technologies.

Zhao and his colleagues are also investigating whether a megakaryocyte niche can be used to help expand human hematopoietic stem cells in vitro and stem cell transplantation for patients.

Hematopoietic stem cell transplantation (HSCT) is a therapeutic option for many patients with bone marrow failure.

It would have been more appropriate to note that their review targeted hematopoietic stem cell transplantation because embryonic stem cells are not yet ready for clinical use.

As a result, they are currently being investigated as a cellular therapeutic for the treatment of autoimmune diseases and long - term patient and graft survival following solid organ transplantation, and allogeneic hematopoietic stem cell transplantation.

Plerixafor has been approved by the FDA as the first small - molecule CXCR4 antagonist for use in combination with granulocyte - colony stimulating factor (GCSF) to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

This new knowledge has paved the way for the therapeutic transfer of stem cells not only for the treatment of hematopoietic diseases by bone marrow transplantation â $» first attempted by E. Donnall Thomas, one of this bookâ $ ™ s editors, in 1957 â $» but also for the treatment of many other disorders.

Warren D. Shlomchik, M.D. Yale University Memory T cells for improved immune reconstitution and GVL in allogeneic hematopoietic stem cell transplantation

When undergoing treatment for leukemia many patients require hematopoietic stem cell (HSC) transplantation to replace the blood stem... Continue reading Mice pave the way to a cord blood transplant advance

Human placenta and chorion: potential additional sources of hematopoietic stem cells for transplantation.

These allogeneic cells have the potential to participate in immune surveillance for breast or other cancers as observed in clinical hematopoietic stem cell transplantation.

But until gene therapy is more commonplace, the only curative treatment for sickle cell is hematopoietic stem cell transplantation.

Today, this study presents tangible progress for patients with a devastating genetic brain disease and opens the door for application to other neurological diseases that are treatable with hematopoietic stem - cell transplantation.

Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, de Lima M, Gupta V, Keating A, Lazarus HM, Litzow MR, Marks DI, Maziarz RT, Rizzieri DA, Schiller G, Schultz KR, Tallman MS, Weisdorf D. Hematopoietic stem - cell transplantation for acute leukemia in relapse or primary induction failure.